Tag:

Generics

Latest Headlines

Latest Headlines

AstraZeneca unveils direct-to-patient Nexium delivery to fend off generic rivals

AstraZeneca is staring down the barrel of its Nexium patent loss, but it's doing its best to dodge the bullet. In a bid to keep patients hooked on the branded version of that purple pill, the company will sell Nexium to them directly--and at a discount.

Pfizer's billion-dollar Celebrex patent loss has Mylan, Actavis revving up generics

One of Pfizer's top-selling products is suddenly vulnerable to generic competition 18 months earlier than expected. A U.S. court nixed a key Celebrex patent, putting the pain drug up for a sales fight in May. And generics makers Mylan and Actavis are promising to launch their versions as soon as Pfizer's monopoly expires.

AstraZeneca set for earnings boost if Ranbaxy can't deliver a Nexium generic

AstraZeneca may get lucky with Nexium. That's thanks to the embattled Ranbaxy Laboratories, the Indian generics maker that could launch a copycat version May 27.

Pfizer recalls 104,000 bottles of antidepressant Effexor XR

The largest drugstore chains have been in a legal battle with Pfizer, accusing it of conspiring to keep generics of its antidepressant Effexor XR out of their stores for years. Now they will have to deal with losing some of the real thing. Pfizer is recalling three lots of the drug after a pharmacist discovered a capsule of one of Pfizer's heart pills in an Effexor XR bottle, a potentially fatal combo.

Teva keeps battling Natco over generic of blockbuster Copaxone

Teva Pharmaceutical Industries is trying to throw up yet another hurdle to a generic version of its blockbuster multiple sclerosis drug Copaxone from India's Natco Pharmaceuticals. 

Generic makers to FDA: Labeling rule risky for patients, adds $4B in annual costs

Generic drug companies are fighting back against a new FDA proposal that would require them to update product labeling as soon as they learn of new safety information. The rule would essentially overturn a 30-year-old law--and put companies on the hook for liability lawsuits.

Ranbaxy scrambles to fix problems that challenge its exclusives

In an effort to get itself into a place where it can again ship from its FDA-approved plants in India, Ranbaxy Laboratories says it is taking a hard look at how it runs its API operations.

The FDA is quietly testing some drugs for generic equivalency

Generics make up about 80% of the drugs U.S. consumers use, but there has long been questions about whether some of them work as well as the products they mimic. Now the FDA is finding out.

With Teva's Symbicort copy nearing EU launch, AstraZeneca preps for battle

An EU drug-review committee recommended Teva Pharmaceutical Industries' knockoff version of the AstraZeneca respiratory med Symbicort on Friday. With key patents already expired, Teva's DuoResp Spiromax could soon put AstraZeneca's brand under siege.

Antitrust watchdogs come down on Pfizer for Lipitor dealmaking

The antitrust crackdown in pharma has moved to Australia. Once again, Pfizer finds itself in the middle of a legal fight over its efforts to hang onto Lipitor sales after the drug went off patent and faced competition from cheaper generics.